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Objective: The objective of this selective EBM review is to determine whether or not “Does 
Lactobacillus reuteri DSM 17938 reduce daily crying times in infants with colic?” 
 
Study Design: Review of all English language primary studies published in 2010, 2013, 2015. 
 
Data Sources: Three randomized, double blind, placebo controlled clinical trials found using 
PubMed.  
 
Outcomes Measured: Daily average crying times were measured by parents who documented 
these in a journal.  
 
Results: In all three randomized control studies by Chaeu et al. (2015), Savino et al, (2010), and 
Szajewska et al. (2013), they found that infants with colic given Lactobacillus reuteri DSM 
17938 had reduced daily crying times as documented by the parents compared to the infants with 
colic given a placebo that looked and tasted the same.  
 
Conclusion: All three randomized control trials included in this review indicate that 
Lactobacillus reuteri DSM 17938 reduces the daily crying times in infants with colic.  
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Introduction 
Colic is a benign self-limited condition that resolves within a couple of months and has 
no standard definition. Clinically, it can be defined by the Wessel’s criteria as crying for no 
apparent reason for > 3 hours per day and occurs on > 3 days per week in healthy infants <3 
months of age.1 This paper evaluates three randomized, double-blind, placebo- controlled trials 
to determine the efficacy of Lactobacillus reuteri DSM 17938 for improving average crying 
times for infants with colic. 
 There are no clearly defined estimates for the prevalence of colic due to provider 
differences in diagnostic criteria, populations, and family perceptions. Estimates of the 
prevalence of colic in infants range from approximately 8 to 40 percent.1 The exact total 
healthcare cost for infantile colic has not been identified either due to the challenges of properly 
diagnosing colic.1 Furthermore, it is unknown the exact estimate of healthcare costs to treat colic 
due to the differences as well.1   
The etiology of infantile colic is unknown; however, it is thought to be due to 
gastrointestinal, biologic, and psychosocial reasons. Gastrointestinal reasons include faulty 
feeding techniques, cow’s milk protein intolerance, lactose intolerance, gastrointestinal 
immaturity, intestinal hypermobility, and alterations in fecal micro flora. Biologic reasons 
include immature motor regulation, increased serotonin, maternal smoking during pregnancy and 
post-partum, and early form of migraines. Psychosocial reasons include temperament, 
hypersensitivity, and parental variables.1  
Current treatment methods differ widely. These treatments are mostly trying to control 
the infants’ comfort levels and to help with the parents’ quality of life. There is no current cure 
for infantile colic. About 80-90% of infants with colic have complete resolving of symptoms by 
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four months of age.1 Treatment methods include soothing techniques including pacifiers, taking 
the infant for a car ride, rocking, warm baths, and changing feeding techniques. Many parents are 
encouraged to also change from milk-based formula to extensive hydrolysate formula, soy 
protein formula, lactose-free formula, herbal teas, or fiber-enriched formula. These treatments 
have not shown to provide great improvement in the infants’ symptoms. Also, parental support 
and education is offered to help the parents care for their child and decrease the stress brought on 
by an infant with colic. It is thought that the cause of colic stems from gastrointestinal 
disturbances; therefore, the Lactobacillus reuteri DSM 17938 addresses this problem. 1  
Objective 
 The objective of this selective EBM review is to determine whether or not “Does 
Lactobacillus reuteri DSM 17938 reduce daily crying times in infants with colic?” 
Methods	  This	  investigation	  looks	  at	  three	  randomized,	  double	  blind,	  placebo	  controlled	  clinical	  trials.	  In	  order	  to	  participate	  in	  the	  studies	  the	  infants	  had	  to	  be	  <	  6	  months	  of	  age	  and	  diagnosed	  with	  infantile	  colic	  by	  the	  Wessel’s	  criteria.	  All	  studies	  included	  
Lactobacillus	  reuteri	  DSM	  17938	  as	  intervention	  therapy.	  In	  all	  studies, the comparison 
group’s therapy was a placebo identical in appearance and taste. The main outcome looked at for 
the purpose of this paper was reduction in average crying times.  
The author performed searches using the PubMed databases using the key words of 
infantile colic, Lactobacillus reuteri DSM 17938, and reduced cry times. All searches performed 
were set for English language. All articles searched were published in peer-reviewed journals 
after the year 2010 and were selected based on relevance and importance of outcome to the 
patient. Inclusion criteria for the purpose of this paper included randomized, double blind 
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controlled studies that included POEMs and exclusively breastfed infants. Exclusion criteria 
included previous Cochrane reviews, previous student published systematic reviews, and infants 
> 6 months. All studies used similar statistics such as p-value, NNT, RBI, ABI to evaluate the 
outcomes. The demographics of the studies are included and outlined below in Table 1. 






















-diagnoses with colic by 
Wessel criteria 
-age 3 weeks to 6 
months 
-exclusively breastfed 
- term delivery (>37wks) 
- 5 minute APGAR 
score > 7 
-birth weight > 2500 g 
-a major medical problem or 
acute illness, including gastro 
esophageal reflux 
-history of ABX tx before or 
during the study 
- history of probiotic or L 
reuteri supplementation 
-history of any allergies to any 
of the ingredients of the 
probiotic 
-concurrent participation in 
another clinical trial 
0 Lactobacillus 
reuteri DSM 
17938, 5 drops 
orally once 










- recruited from general 
pediatricians and 
outpatients at the 
Department of 
Pediatrics, University of 
Turin between March 
2008 and August 2009 
-exclusively breastfeed  
-mothers avoided cow’s 
milk in their diet, 
-clinical evidence of chronic 
illness or GI disorders 
-intake of probiotics and/or 
antibiotics in the week 
preceding recruitment 
-formula feeding 
no acid blockers used 
4 Lactobacillus 
reuteri DSM 














-full term infants aged < 
5 months 
- diagnosed with colic 
by Wessel’s criteria 
-exclusively or 
predominately breastfed 
-acute or chronic illness 
-gastrointestinal disorders 
-use of any ABX and/or 
probiotics pharmaceutical 
products within 7 days prior 
to the study 
0 Lactobacillus 
reuteri DSM 
17938, 5 drops 
orally once 
daily for 21 
days 
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Outcomes 
All the studies measured the reduction in the duration of average crying and fussing 
times. Parents were instructed to keep a diary to record frequency of colic episodes, daily crying 
times, feeding schedule, stool frequency, stool characteristics, and any adverse events 
experienced. 
Results 
All three articles reviewed were randomized double blind, placebo controlled studies, and 
they all assessed the efficacy of Lactobacillus reuteri DSM 17938 in reducing the crying times of 
infants diagnosed with colic. All three used a placebo that was similar in appearance and taste to 
the Lactobacillus reuteri DSM 17938. Furthermore, all three studies randomized their sample 
population and matched them to the experimental and control groups.  
Chau et al. had 55 eligible infants enrolled in the study based on inclusion and exclusion 
criteria as in Table 1. There were 27 assigned to receive placebo while 28 were assigned to 
receive L. reuteri. They had three participants from the L. reuteri group withdrawn from the trial 
and not included in the analysis.2 No adverse reactions were reported in the treatment or placebo 
group. At the end of the treatment period (day 21), the L. reuteri group exhibited a significantly 
greater reduction in daily crying and fussing time. The average daily crying times for the 
treatment group was 60 minutes (IQR 64) compared to the placebo group being 102 minutes 
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Table 2: Primary outcome: duration of crying and/or fussing times in the placebo and L 
reuteri DSM 17938 groups 




Baseline 122 (163-88) 131 (149-84) 9 (-29 to 46) .804 
Day 7 120 (149-91) 90 (129-53) -30 (-65 to 5) .032 
Day 14 103 (140-78) 75 (103-54) -28 (-55 to 0) .018 
Day 21 102 (148-61) 60 (99-35) -42 (-74 to -10) .045 
Szajewska et al. had 80 infants enrolled in the study based on inclusion and exclusion 
criteria as in Table 1. There were 40 infants assigned to receive placebo while 40 were assigned 
to receive L. reuteri. There were no participants that were withdrawn. No adverse reactions were 
reported in the treatment or placebo group.3 At the end of the treatment period (day 28), the L. 
reuteri group exhibited a significantly greater reduction in daily crying and fussing time. The 
average daily crying times for the treatment group was 52 minutes (IQR: 30) compared to the 
placebo group being 120 minutes (IQR: 38). P- value was <.0001 which is statistically 
significant.3   
Table 3: Primary outcome: duration of crying and/or fussing times in the placebo and L 
reuteri DSM 17938 groups 
 








Baseline 240 (210-270) 240 (203-278) 0.0 (-30 to 30) .8 
Day 7 180 (149-180) 180 (150-210)  0.0 (-60 to 0) .002 
Day 14 105 (101-120) 150 (120-180) -45 (-75 to -30) <.0001 
Day 21 75 (60-90) 128 (116-150) -53 (-83 to -45) <.0001 
Day 28 52 (45-75) 120 (90-128) -68 (-75 to -60) <.0001 
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Savino et al. had 50 infants in the study based on inclusion and exclusion criteria as Table 
1.  Four patients were withdrawn from the placebo group analysis due to fever, failure to 
complete the diary, or GERD. There were 21 assigned to receive placebo while 25 were assigned 
to receive L reuteri.4 There were no withdrawals due to adverse effects related to the trial. 
Adverse events reported during the study were rhinitis, eczema, fever, otalgia, and gastro 
esophageal reflux. At the end of the treatment period (day 21), the L reuteri group exhibited a 
significantly greater reduction in daily crying and fussing time. The average daily crying times 
for the treatment group was 35 minutes (IQR: 85) compared to the placebo group being 90 
minutes (IQR: 148). P- value was .022 which is statistically significant.4 
Table 4: Primary outcome: duration of crying and/or fussing times in the placebo and L 
reuteri DSM 17938 groups 
 L reuteri group 
(n=25), Median (IQR) 
Placebo group (n=21), 
Median (IQR) 
P- value 
Baseline 370 (120) 300 (150) .127 
Day 7 95 (85) 185 (149) .082 
Day 14 60 (70) 150 (145) .099 
Day 21 35 (85) 90(148) .022 
 
Discussion 
All studies were very similar in patient population, sample size, inclusion criteria, 
exclusion criteria, sample size, methods, and results. They all had the same general outcomes as 
well. The only difference is Savino et al addresses bacteria in the stools. They took stool samples 
throughout the trial to evaluate the bacteria concentrations such as E. coli.4  
Currently, Lactobacillus is mostly offered over the counter for infants and children. It is 
available as drops, capsules, caplets, granules, powder, tablets, chewable tablets, and wafers. It is 
Kolle,	  Lactobacillus	  in	  infantile	  colic	   9	  
also available as an intramuscular injection.5 Gerber Soothe colic drops, which are L. reuteri 
drops, cost about $24.99 on average.6 These drops are marketed to help improve good bacteria in 
an infant’s digestive system, which helps to promote digestive comfort. Parents have complained 
of excess flatulence and bloating while the infant is taking these probiotic drops. It is 
recommended to use caution with patients who are immunocompromised because it is a live 
bacterium. Because probiotics are classified as dietary supplements, there are no safety reviews 
and approved indications by the FDA.  Furthermore, there are currently no black box warnings 
or known drug interactions.5  
 One limitation for these studies was sample size. The sample sizes were 50, 52, and 
80.2,3,4 Another limitation was the parents’ accuracy in documenting the daily average crying 
times, and all the studies discussed this limitation.  The parents’ perceptions of the crying times 
vary, and the time that the parents document the crying times could change the accuracy of the 
crying times documented. One study was concerned parents would wait until the day of the 
infant’s appointment to document all the crying times.3 Compliance was also not assessed in two 
studies.  It is hard to definitely classify crying times when it is based on many different parents’ 
perceptions versus crying times determined by a single person.  
Conclusion 
 After reviewing these three studies, evidence strongly suggests that Lactobacillus reuteri 
DSM 17938 does reduce daily crying times in infants with colic. The studies followed the 
participants for an appropriate amount of time, and although the sample sizes were relatively 
smaller in each study, the results found were still considered statistically significant. The 
limitation with these studies is there was no objective way to measure crying times. The studies 
had to rely on the parents to document the crying times daily in a diary. One way to fix this 
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limitation would be to have voice-activated recorders to measure the crying times. One area of 
thought for further research about infantile colic was discussed by Savino et al. They checked 
stool samples. They determined that there was an increase in the probiotic in the stool and a 
decrease in E.coli.2 E. coli has been found to be in higher concentrations in the stool of those 
infants with colic than those infants without colic.2 There should be a further study to determine 
if E. coli decreasing in the stool decreases the crying times in the infants as well. This would also 
provide a more objective way to determine if infantile colic is due to gastrointestinal symptoms. 
Also, future study is warranted to determine if infantile colic predisposes infants to have 
recurrent abdominal pain, allergic diseases, or psychological disorders later in life. This study 
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